×
About 1,325,596 results

Covid-19 makes us face the hazy line between ‘elective’ and ‘essential’ medicine
https://www.washingtonpost.com/outlook/coronavirus-elective-essential-medicine/2020/06/18/d1942ea2-af1e-11ea-8758-bfd1d045525a_story.html

Pralsetinib Active Across RET+ Tumor Types and Gains FDA Review
https://www.onclive.com/view/pralsetinib-active-across-emretem-tumor-types-and-gains-fda-review-

May 31st, 2020

MGD013 Demonstrates Encouraging Activity Across Tumor Types
https://www.onclive.com/view/mgd013-demonstrates-encouraging-activity-across-tumor-types

May 31st, 2020

For the Frontlines
https://www.forthefrontlines.org/

Health care professionals and essential workers are showing up on the frontlines during the coronavirus pandemic—risking their health every day to help other people. They need fast, free crisis counseling at their fingertips, 24/7. Crisis Text Line, Shout, and Kids Help Phone are here for the frontlines. Text FRONTLINE for support to dealing with anxiety, stress, fear, isolation, or other d...

Project Parachute
https://project-parachute.org/index.html

Health care workers across the country are facing unprecedented challenges as they work to contain COVID-19. I'm Stephanie Zerwas, a psychologist in private practice at Flourish Chapel Hill as well as an Associate Professor at UNC Psychiatry. In cooperation with Eleos Health, we aim to provide pro-bono therapy for front line health care professionals.

Physician Support Line
https://www.physiciansupportline.com/

1 (888) 409-0141 Helping our colleagues all over the U.S. on the front lines of COVID-19 Free & Confidential | No appointment necessary

Likelihood of survival of coronavirus in a respiratory droplet deposited on a solid surface
https://aip.scitation.org/doi/10.1063/5.0012009

We predict and analyze the drying time of respiratory droplets from a COVID-19 infected subject, which is a crucial time to infect another subject. Drying of the droplet is predicted by using a diffusion-limited evaporation model for a sessile droplet placed on a partially wetted surface with a pinned contact line. The variation in droplet volume, contact angle, ambient temperature, and humidit...

ECOG-ACRIN Trial Reassures Clinicians, Patients That Locoregional Therapy Is Not Beneficial for Stage IV Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200218/full/

Jun 23rd, 2020 - For patients with stage IV metastatic breast cancer and an intact primary tumor (ITP), the early initiation of locoregional treatment (LRT) was not associated with longer survival or improvements in health-related quality of life (HRQoL) compared with systemic therapy alone, according to a phase III clinical trial (Abstract LBA2). These findings appear to add to a robust evidence base that sugg...

Will DFS Benefit Translate Into Survival Benefit in ADAURA?
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200221/full/

Jun 23rd, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...

Clinical Implications of First-Line Pembro for MSI-High mCRC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200220/full/

Jun 23rd, 2020 - Long-awaited results from the randomized, phase III KEYNOTE-177 trial provide strong support for using single-agent pembrolizumab instead of a chemotherapy-based regimen in patients newly diagnosed with metastatic colorectal cancer (mCRC) featuring high-level microsatellite instability (MSI-H) or deficient mismatch repair (dMMR; Abstract LBA4).

Researchers gain insight into factors influencing immunotherapy response in kidney cancer
https://www.healio.com/news/hematology-oncology/20200710/researchers-gain-insight-into-factors-influencing-immunotherapy-response-in-kidney-cancer

Jul 9th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to be more effective in treating tumors with high mutational burden. However, despite having only a moderate number of mutations, advanced clear cell ren...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Povidone iodine
https://www.nature.com/articles/s41415-020-1589-4
BDJ

Sir, dentists and their assistants as front-line healthcare workers (HCW) in close contact with the upper aerodigestive tract are at especial risk of transmission of the coronavirus from patients. In early infection, viral titres of greater than 107/mL in saliva and nasal mucous can be found and thus any work within the oral cavity carries an increased risk.1 Even a few microlitres of saliva co...

Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273282/

Top 20 Research Studies of 2019 for Primary Care Physicians
https://www.aafp.org/afp/2020/0515/p608.html

In 2019, regular surveillance of 110 English-language research journals identified 254 studies that met the criteria to become POEMs (patient-oriented evidence that matters). Physician members of the Canadian Medical Association rated these POEMs for their relevance to patients in their practices. This article summarizes the clinical questions and bottom-line answers from the top 20 POEMs of 20...

Metastatic Urothelial Cancer: A Conversation on State-of-the-Art Treatment Before the ASCO20 Virtual Scientific Program
https://ascopost.com/videos/asco20-virtual-scientific-program/metastatic-urothelial-cancer-a-conversation-before-the-asco20-virtual-scientific-program/

May 25th, 2020 - As Thomas Powles, MD, PhD, of Queen Mary University of London, prepares to deliver his late-breaking presentation at the ASCO20 Virtual Scientific Program (LBA-1), he talks with Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, about current therapy: PD1/PDL1 inhibition in second-line treatment and as monotherapy in the first-line setting, as well as the concept of maintenance switch.

David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue?
https://ascopost.com/videos/asco20-virtual-scientific-program/david-wise-on-novel-biomarkers-in-prostate-cancer/

May 29th, 2020 - David R. Wise, MD, PhD, of New York University Perlmutter Cancer Center, summarizes three important studies in prostate cancer: circulating tumor cell count as a prognostic marker of PSA response and progression in metastatic castration-sensitive disease; new phenotypic subtypes; and how circulating tumor DNA dynamics associate with treatment response and radiologic progression-free survival (A...

Antiinflammatory and Antiarthritic Activities of Some Foods and Spices
https://www.sciencedirect.com/science/article/pii/B9780128138205000040
Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases;

Green herbs and seeds of fenugreek (Trigonella foenum-graecum Linn.), rhizomes of turmeric (Curcuma longa Linn.,) and ginger (Zingiber officinale Roscoe) used as foods and spices in many Asian countries are claimed to be useful in relieving pain, inflammation, and arthritis. This review describes the scientific data evaluating these claims. Fatty acids, flavonoids, saponins, alkaloids (trigonel...

First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer
https://ascopost.com/news/may-2020/first-line-pembrolizumab-plus-etoposideplatinum-for-extensive-stage-small-cell-lung-cancer/

May 29th, 2020 - As reported at the ASCO20 Virtual Scientific Program by Charles M. Rudin, MD, PhD, and colleagues (Abstract 9001), the phase III KEYNOTE-604 trial has shown that first-line pembrolizumab plus etoposide/platinum significantly prolonged progression-free survival and prolonged overall survival at a near significant level vs placebo plus etoposide/platinum in patients with extensive-stage small cel...

Adjuvant Osimertinib ‘Exceeds Expectations’ in Early-Stage EGFR-Positive NSCLC
https://ascopost.com/news/may-2020/adjuvant-osimertinib-exceeds-expectations-in-egfr-positive-nsclc/

May 27th, 2020 - Adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA ­EGFR-mutated non–small cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated. These results from the first interim analysis of the phase III ADAURA trial were reported at the ASCO20 Virtual Scientific Program and f...